Trial Profile
A Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FALCON
- Sponsors Reata Pharmaceuticals
- 12 Jul 2023 This trial has been completed in Germany (Date of the global end of the trial: 06-Jul-2023), according to the European Clinical Trials Database record.
- 11 Jul 2023 This trial has been completed in France, according to European Clinical Trials Database record.
- 04 Jul 2023 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.